Wall Street analysts expect Corium International Inc (NASDAQ:CORI) to report sales of $7.07 million for the current quarter, according to Zacks. Two analysts have issued estimates for Corium International’s earnings, with estimates ranging from $6.57 million to $7.57 million. Corium International posted sales of $7.35 million during the same quarter last year, which suggests a negative year over year growth rate of 3.8%. The company is expected to announce its next earnings report on Thursday, May 10th.
On average, analysts expect that Corium International will report full year sales of $7.07 million for the current fiscal year, with estimates ranging from $31.97 million to $33.93 million. For the next fiscal year, analysts anticipate that the company will post sales of $39.28 million per share, with estimates ranging from $38.82 million to $39.74 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover Corium International.
Corium International (NASDAQ:CORI) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.06. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%. The business had revenue of $9.32 million during the quarter, compared to the consensus estimate of $7.48 million.
Shares of CORI stock traded up $0.34 during mid-day trading on Thursday, reaching $11.56. 1,637,968 shares of the company’s stock were exchanged, compared to its average volume of 379,328. Corium International has a twelve month low of $3.50 and a twelve month high of $13.93. The company has a quick ratio of 1.34, a current ratio of 1.40 and a debt-to-equity ratio of 5.91. The company has a market cap of $417.59, a P/E ratio of -7.32 and a beta of 1.50.
In other Corium International news, major shareholder Perceptive Advisors Llc acquired 50,350 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was bought at an average cost of $11.83 per share, with a total value of $595,640.50. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Life Sciences Maste Perceptive acquired 510,000 shares of the business’s stock in a transaction that occurred on Thursday, January 18th. The stock was acquired at an average cost of $12.54 per share, with a total value of $6,395,400.00. The disclosure for this purchase can be found here. 30.80% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RTW Investments LP boosted its holdings in Corium International by 1.4% in the 4th quarter. RTW Investments LP now owns 1,699,653 shares of the biopharmaceutical company’s stock worth $16,334,000 after buying an additional 24,174 shares during the period. BlackRock Inc. boosted its holdings in Corium International by 42.1% in the 4th quarter. BlackRock Inc. now owns 1,679,815 shares of the biopharmaceutical company’s stock worth $16,143,000 after buying an additional 497,615 shares during the period. Opaleye Management Inc. boosted its holdings in Corium International by 15.2% in the 4th quarter. Opaleye Management Inc. now owns 1,060,000 shares of the biopharmaceutical company’s stock worth $10,186,000 after buying an additional 140,000 shares during the period. Tamarack Advisers LP boosted its holdings in Corium International by 6.3% in the 4th quarter. Tamarack Advisers LP now owns 1,010,000 shares of the biopharmaceutical company’s stock worth $9,706,000 after buying an additional 60,000 shares during the period. Finally, State Street Corp bought a new position in Corium International in the 2nd quarter worth approximately $1,840,000. 88.58% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “$7.07 Million in Sales Expected for Corium International Inc (CORI) This Quarter” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://sportsperspectives.com/2018/03/18/7-07-million-in-sales-expected-for-corium-international-inc-cori-this-quarter.html.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.